US-based Arcturus working with Duke-NUS on single-dose Covid-19 vaccine plans phase 3 trials

More than 354 million doses of various Covid-19 vaccines have reportedly been administered across 121 countries.
More than 354 million doses of various Covid-19 vaccines have reportedly been administered across 121 countries.PHOTO: ST FILE

SINGAPORE - United States-based Arcturus Therapeutics, which is jointly developing a Covid-19 vaccine with the Duke-NUS Medical School in Singapore, is preparing to test a single low-dose shot of its messenger RNA vaccine in large trials that will start in the second quarter of the year.

The 5 microgram single-dose regimen will also be a lyophilised, or freeze-dried, version that will be easier and less costly to distribute and store. It will not require the cold chain storage and transport that the usual mRNA vaccine in frozen liquid form needs.

Please or to continue reading the full article.

Get unlimited access to all stories at $0.99/month

  • Latest headlines and exclusive stories
  • In-depth analyses and award-winning multimedia content
  • Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months*

*Terms and conditions apply.